B. Metzler Seel. Sohn & Co. Ag Alnylam Pharmaceuticals, Inc. Transaction History
B. Metzler Seel. Sohn & Co. Ag
- $9.53 Billion
- Q4 2024
A detailed history of B. Metzler Seel. Sohn & Co. Ag transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, B. Metzler Seel. Sohn & Co. Ag holds 3,279 shares of ALNY stock, worth $929,071. This represents 0.01% of its overall portfolio holdings.
Number of Shares
3,279
Previous 3,279
-0.0%
Holding current value
$929,071
Previous $901,000
14.43%
% of portfolio
0.01%
Previous 0.01%
Shares
7 transactions
Others Institutions Holding ALNY
# of Institutions
671Shares Held
112MCall Options Held
839KPut Options Held
771K-
Capital World Investors Los Angeles, CA16.6MShares$4.7 Billion0.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.7MShares$3.61 Billion0.05% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.71 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA6.97MShares$1.97 Billion0.35% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.38MShares$1.24 Billion0.64% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $34.9B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...